JP2022545387A - がんの処置方法 - Google Patents

がんの処置方法 Download PDF

Info

Publication number
JP2022545387A
JP2022545387A JP2022509196A JP2022509196A JP2022545387A JP 2022545387 A JP2022545387 A JP 2022545387A JP 2022509196 A JP2022509196 A JP 2022509196A JP 2022509196 A JP2022509196 A JP 2022509196A JP 2022545387 A JP2022545387 A JP 2022545387A
Authority
JP
Japan
Prior art keywords
entrectinib
patient
cancer
administration
grade
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022509196A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545387A5 (enExample
Inventor
ジョージナ メネセス－ロレンテ
エドナ チョウ マネヴァル
プラティク エス． マルタニ
スーザン ダイアン エン
アコスタ セルジオ レネ レイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2022545387A publication Critical patent/JP2022545387A/ja
Publication of JP2022545387A5 publication Critical patent/JP2022545387A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2022509196A 2019-08-14 2020-08-13 がんの処置方法 Pending JP2022545387A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962886948P 2019-08-14 2019-08-14
US62/886,948 2019-08-14
PCT/US2020/046229 WO2021030619A1 (en) 2019-08-14 2020-08-13 Methods of treating cancer

Publications (2)

Publication Number Publication Date
JP2022545387A true JP2022545387A (ja) 2022-10-27
JP2022545387A5 JP2022545387A5 (enExample) 2023-08-18

Family

ID=72266851

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022509196A Pending JP2022545387A (ja) 2019-08-14 2020-08-13 がんの処置方法

Country Status (6)

Country Link
US (1) US20220257592A1 (enExample)
EP (1) EP4013404A1 (enExample)
JP (1) JP2022545387A (enExample)
CN (1) CN114222576A (enExample)
TW (1) TW202114676A (enExample)
WO (1) WO2021030619A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230454A1 (en) * 2022-05-24 2023-11-30 Icahn School Of Medicine At Mount Sinai Neurotrophic tyrosine receptor kinase inhibitors as therapeutics for liver disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018140093A1 (en) * 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299057B2 (en) 2007-07-20 2012-10-30 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018140093A1 (en) * 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLIN. CANCER RES., vol. 19, JPN6024024930, 2013, pages 3631 - 3639, ISSN: 0005557659 *
HEPATOLOGY, vol. 29, JPN6024024929, 1999, pages 1643 - 1648, ISSN: 0005557658 *
HISTORY OF CHANGES FOR STUDY: NCT04226833, JPN6024024926, 11 August 2020 (2020-08-11), ISSN: 0005557660 *
THER. CLIN. RISK MANAG., vol. 14, JPN6024024927, 2018, pages 1247 - 1252, ISSN: 0005557657 *

Also Published As

Publication number Publication date
TW202114676A (zh) 2021-04-16
CN114222576A (zh) 2022-03-22
EP4013404A1 (en) 2022-06-22
WO2021030619A1 (en) 2021-02-18
US20220257592A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
AU2016370846B2 (en) Combinations for the treatment of cancer
TWI785074B (zh) 醫藥組合物及劑型
US20170356918A1 (en) Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
CN111225662B (zh) 药物组合物和剂型
EP3490561A1 (en) Combinations for the treatment of cancer
TW201821078A (zh) 治療癌症之方法
US20220257592A1 (en) Methods of treating cancer
HK40069081A (en) Methods of treating cancer
BR122025029354A2 (pt) Método para preparar composição farmacêutica
HK40016507A (en) Pharmaceutical compositions comprising entrectinib
CN118632696A (zh) 包含fgfr抑制剂和kras抑制剂的组合疗法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230809

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250325